TY - JOUR
T1 - Soluble RAGE Prevents Type 1 Diabetes Expanding Functional Regulatory T Cells
AU - Leung, Sherman S
AU - Borg, Danielle J
AU - McCarthy, Domenica A
AU - Boursalian, Tamar E
AU - Cracraft, Justen
AU - Zhuang, Aowen
AU - Fotheringham, Amelia K
AU - Flemming, Nicole
AU - Watkins, Thomas
AU - Miles, John J
AU - Groop, Per-Henrik
AU - Scheijen, Jean L
AU - Schalkwijk, Casper G
AU - Steptoe, Raymond J
AU - Radford, Kristen J
AU - Knip, Mikael
AU - Forbes, Josephine M
N1 - © 2022 by the American Diabetes Association.
PY - 2022/9
Y1 - 2022/9
N2 - Type 1 diabetes is an autoimmune disease with no cure, where clinical translation of promising therapeutics has been hampered by the reproducibility crisis. Here, short-term administration of an antagonist to the receptor for advanced glycation end products (sRAGE) protected against murine diabetes at two independent research centers. Treatment with sRAGE increased regulatory T cells (T-regs) within the islets, pancreatic lymph nodes, and spleen, increasing islet insulin expression and function. Diabetes protection was abrogated by T-reg depletion and shown to be dependent on antagonizing RAGE with use of knockout mice. Human T-regs treated with a RAGE ligand downregulated genes for suppression, migration, and T-reg homeostasis (FOXP3, IL7R, TIGIT, JAK1, STAT3, STAT5b, CCR4). Loss of suppressive function was reversed by sRAGE, where T-regs increased proliferation and suppressed conventional T-cell division, confirming that sRAGE expands functional human T-regs. These results highlight sRAGE as an attractive treatment to prevent diabetes, showing efficacy and reproducibility at multiple research centers and in human T cells.
AB - Type 1 diabetes is an autoimmune disease with no cure, where clinical translation of promising therapeutics has been hampered by the reproducibility crisis. Here, short-term administration of an antagonist to the receptor for advanced glycation end products (sRAGE) protected against murine diabetes at two independent research centers. Treatment with sRAGE increased regulatory T cells (T-regs) within the islets, pancreatic lymph nodes, and spleen, increasing islet insulin expression and function. Diabetes protection was abrogated by T-reg depletion and shown to be dependent on antagonizing RAGE with use of knockout mice. Human T-regs treated with a RAGE ligand downregulated genes for suppression, migration, and T-reg homeostasis (FOXP3, IL7R, TIGIT, JAK1, STAT3, STAT5b, CCR4). Loss of suppressive function was reversed by sRAGE, where T-regs increased proliferation and suppressed conventional T-cell division, confirming that sRAGE expands functional human T-regs. These results highlight sRAGE as an attractive treatment to prevent diabetes, showing efficacy and reproducibility at multiple research centers and in human T cells.
U2 - 10.2337/db22-0177
DO - 10.2337/db22-0177
M3 - Article
C2 - 35713929
SN - 0012-1797
VL - 71
SP - 1994
EP - 2008
JO - Diabetes
JF - Diabetes
IS - 9
ER -